Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

BRISBANE, Calif., Nov. 7, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2012.   

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

InterMune reported Esbriet® (pirfenidone) net revenue in the third quarter of 2012 of $7.5 million, approximately 91 percent of which was from Germany, which was the first country in which Esbriet was launched in September 2011.  Esbriet revenue was $0.1 million in the third quarter of 2011 which reflected less than one month's revenue of Esbriet from Germany.  Esbriet is InterMune's product marketed in Europe for adults with mild-to-moderate idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease of the lungs.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We are pleased to report this quarter many important accomplishments by our European and Canadian businesses and continued sequential quarterly growth in Esbriet sales since its first launch in Europe in September of 2011."  

Mr. Welch continued, "With continued successful completion of the pricing and reimbursement processes and Esbriet launches throughout Europe over the coming months, along with the planned launch of Esbriet in Canada on January 1, 2013, we have begun a period of sustained annual sales growth.  We also expect that our ASCEND Phase 3 study, which is nearing full enrollment, will lead to positive top-line data in the first half of 2014 and the launch of Esbriet in the U.S., providing further acceleration of our sales growth."Esbriet® (pirfenidone) Third Quarter Accomplishments and Recent Highlights

  • On September 11, 2012, InterMune announced t
    '/>"/>

    • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune To Release Third Quarter Financial Results On November 7
    2. InterMune To Present At JMP Securities Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune to Present at J. P. Morgan Healthcare Conference
    5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
    8. Patient Safety Technologies Reports Third Quarter 2012 Results
    9. PDI Reports 2012 Third Quarter Financial Results
    10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    11. Neurocrine Biosciences Reports Third Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
    (Date:6/18/2013)... WATERLOO, Ont. (Monday, June 17, 2013) A million electric ... end of the decade with the help of research by ... and the University of Waterloo. , Professor Zhongwei Chen is ... Laboratory looking to develop non-precious materials to replace the expensive ... barriers to the adoption of fuel cells in vehicles is ...
    (Date:6/18/2013)... CA (PRWEB) June 18, 2013 (PRWEB) June 18, ... #1 time and attendance system in North America, ... that shares employee data and payroll records between ... AccountLinx Plus automates ExakTime software setup and ... software imports employee data from a business’ current ...
    (Date:6/18/2013)... The human skin is the largest organ, ... human body part. Similar to the liver, or heart, the ... repair and grow. Recent reports from the mankatofreepress.com explained how ... as important as other life supporting organs. The article suggests ... cell reproduction, increase the appearance of skin, and fight off ...
    Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2ExakTime Introduces AccountLinx Plus 2Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2
    ... Bioscience announced today that it will be participating in ... The conference will be held at the Frontier Airlines ... August 3, 2011. Roka will be located at booth ... introduce a novel molecular instrument platform for the detection ...
    ... -   Text-to-speech application enables researchers to listen ...  Elsevier, a world leading provider of scientific, technical ... of an audio reader application from iSpeech, provider of cloud-based ... . The iSpeech Audio Reader is the latest in a ...
    ... 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... completed the randomized portion of its Phase 3 clinical ... for the treatment of moderate to severe chronic pain, ... "We are very pleased to have brought ...
    Cached Biology Technology:iSpeech® Develops Audio Reader for Elsevier's SciVerse Applications 2iSpeech® Develops Audio Reader for Elsevier's SciVerse Applications 3iSpeech® Develops Audio Reader for Elsevier's SciVerse Applications 4BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 2BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 3
    (Date:6/19/2013)... with extinction as a result of rising human population density, ... University in the US. Their work is also the first ... will continue to pose a threat to other species. In ... above which population growth would cease to have an incremental ... Human Ecology . , It has long been suspected ...
    (Date:6/19/2013)... A decade-long JDRF-funded study led by the Institute ... is providing a deeper understanding of the link ... 1 diabetes (T1D), highlighting the importance of pre-diabetes ... study, "Seroconversion to Multiple Islet Autoantibodies and Risk ... today in The Journal of the American ...
    (Date:6/19/2013)... offers further proof that the divergence of humans from ... was profoundly influenced by mutations to DNA sequences that ... The study, published June 9 in Nature Genetics ... of genes must play an important role in evolution ... in the proteins produced by genes. Indeed, human and ...
    Breaking Biology News(10 mins):Are we pushing animals over the edge? 2New data on islet autoantibodies in young children defines early type 1 diabetes development 2New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
    ... (EMBL) and the German Cancer Research Centre (DKFZ), both ... uncovers the combined effects of genes. Published online today ... different genes can amplify, cancel out or mask each ... interfere with each other in much the same manner ...
    ... Starting rehabilitation sooner following knee arthroplasty surgery could pay ... therapy within 24 hours of surgery can improve pain, ... as cut hospital stays, according to new research in ... Mindful of the trend towards discharging patients from ...
    ... When a Rhode-Island-sized ice chunk separates from Greenland, ... a long-term warmer world? A project called the Scalable, ... on the Jaguar supercomputer at Oak Ridge National Laboratory, ... of ice sheets under a changing climate. ORNL ...
    Cached Biology News:Suggesting genes' friends, Facebook-style 2Rehabilitation within a day of knee replacement pays off 2
    ... chromogenic medium for the detection, isolation, ... S. thyphi) and total coliforms from ... a maximum of 24 hours, needs ... during preparation and performs a higher ...
    ... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
    ... Thermo Scientific ChromQuest Chromatography Data ... control, digital data acquisition, chromatography data ... Scientific Accela High Speed LC. The ... designed to maximize the benefits of ...
    Denhardt's powder mixture (for 50X stock solution)...
    Biology Products: